Schrodinger

Yahoo Finance • last month

Schrodinger downgraded at Citi after clinical program exit

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Citi downgraded Schrodinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a... Full story

Yahoo Finance • last month

Schrödinger discontinues leukemia drug after patient deaths

NEW YORK - Schrödinger, Inc. (NASDAQ:SDGR), a $1.46 billion market cap biotech company with a strong balance sheet showing more cash than debt, announced Thursday it has discontinued the clinical development program for SGR-2921, its CDC7... Full story

Yahoo Finance • last month

Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts

Investing.com - Barclays initiated coverage on Schrodinger (NASDAQ:SDGR) with an Overweight rating and a $25.00 price target on Thursday. The stock, currently trading at $19.84 with a market capitalization of $1.46 billion, has shown volat... Full story

Yahoo Finance • 2 months ago

Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program

Earnings Call Insights: Schrödinger, Inc. (SDGR) Q2 2025 MANAGEMENT VIEW * CEO Ramy Farid highlighted "very solid progress in the first half of 2025" with total revenue of $54.8 million in the second quarter, a 16% increase year-over-y... Full story

Yahoo Finance • 2 months ago

Schrodinger stock maintains Buy rating at Citi on Ajax collaboration

Investing.com - Citi has reiterated a Buy rating and $39.00 price target on Schrodinger (NASDAQ:SDGR) following the company’s announcement of an expanded research collaboration with Ajax Therapeutics. According to InvestingPro data, this t... Full story

Yahoo Finance • 2 months ago

Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration

NEW YORK/CAMBRIDGE - Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR), a $1.56 billion market cap biotech company with robust revenue growth of 22% over the last twelve months, announced Thursday they are expanding their exclusi... Full story

Yahoo Finance • 2 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

NEW YORK & CAMBRIDGE, Mass., July 17, 2025--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. Th... Full story

Yahoo Finance • 3 months ago

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

Investing.com -- Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts in a sector under pre... Full story

Yahoo Finance • 3 months ago

Schrodinger stock rating assumed by Morgan Stanley at Equalweight

Investing.com - Morgan Stanley has assumed coverage on Schrodinger (NASDAQ:SDGR), currently trading at $20.96, with an Equalweight rating and a price target of $28.00, down from the previous $31.00. According to InvestingPro data, the stoc... Full story

Yahoo Finance • 3 months ago

Schrödinger gets Fast Track status for SGR-1505

[Model of DNA molecules connected together with copyspace] AnthiaCumming/E+ via Getty Images * Schrödinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) said that the U.S. FDA granted Fast Track status to its MALT1 inhibitor, SGR... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR).  Such investors are advised to contact Danielle Peyton at new... Full story

Yahoo Finance • 3 months ago

Schrödinger slides after early-stage trial data for cancer therapy

[Diffuse large B-cell lymphoma (DLBCL) - closeup view 3d illustration] Nemes Laszlo Shares of Schrödinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) fell on Thursday after the AI-focused biotech posted initial data from a Phase... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: D-Wave Quantum, Moderna, Agilysys, Tesla and more

Check out the companies making headlines in midday trading. D-Wave Quantum — The quantum computing stock surged more than 26% after announcing its latest computing system called Advantage2. Agilysys — The enterprise software developer for... Full story

Yahoo Finance • 5 months ago

Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against other top stocks in Bill Gates’ portfolio with... Full story

Yahoo Finance • last year

Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology

Initiative initially funded by $10 million grant from the Bill & Melinda Gates Foundation NEW YORK, July 26, 2024--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way thera... Full story

Yahoo Finance • 2 years ago

13 Best Stocks to Buy and Hold According to Bill Gates’ Portfolio

In this article, we will be taking a look at the 13 best stocks to buy and hold according to Bill Gates' Portfolio. To skip our detailed analysis of Bill Gates' stock portfolio, you can go directly to see the 5 Best Stocks to Buy and Hold... Full story

Yahoo Finance • 2 years ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, January 19, 2024--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2024, the compa... Full story

Yahoo Finance • 2 years ago

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

Reports data showing SGR-1505 is well-tolerated and achieves target engagement in Phase 1 healthy volunteer study Highlights expanding portfolio including newly-disclosed EGFRC797S, PRMT5-MTA and NLRP3 programs Outlines broad discovery a... Full story

Yahoo Finance • 2 years ago

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript November 1, 2023 Schrödinger, Inc. misses on earnings expectations. Reported EPS is $-0.86 EPS, expectations were $-0.69. Operator: Welcome to Schrödinger's Conference Call... Full story

Yahoo Finance • 2 years ago

Schrödinger Reports Third Quarter 2023 Financial Results

Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921; Discloses P... Full story